

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number
WO 2023/034783 A1

(51) International Patent Classification:

C07K 14/35 (2006.01) C12N 15/869 (2006.01)
C12N 9/10 (2006.01) A61K 48/00 (2006.01)
C12N 9/52 (2006.01) A61K 39/04 (2006.01)
C12N 15/62 (2006.01)

(21) International Application Number:

PCT/US2022/075645

(22) International Filing Date:

30 August 2022 (30.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/239,278 31 August 2021 (31.08.2021) US
63/392,778 27 July 2022 (27.07.2022) US

(71) Applicant: **VIR BIOTECHNOLOGY, INC.** [US/US];
499 Illinois Street, Suite 500, San Francisco, California
94158 (US).

(72) Inventors: **ARVIN, Ann M.**; 499 Illinois Street, Suite
500, San Francisco, California 94158 (US). **DI IULIO,
Julia**; 499 Illinois Street, Suite 500, San Francisco, Cal-
ifornia 94158 (US). **DOUGLAS, Janet L.**; 499 Illinois

Street, Suite 500, San Francisco, California 94158 (US).
MARSHALL, Emily; 499 Illinois Street, Suite 500, San
Francisco, California 94158 (US). **SORIAGA, Leah B.**;
499 Illinois Street, Suite 500, San Francisco, California
94158 (US). **VIRGIN, Herbert W.**; 499 Illinois Street,
Suite 500, San Francisco, California 94158 (US).

(74) Agent: **PURUSHE, Janaki** et al.; Seed Intellectual Proper-
ty Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle,
Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

(54) Title: TUBERCULOSIS VACCINES

Fusion 6



Fusion 7: Fusion 6 with deletion of RpfA + M72 fusion



Fusion 8: Fusion 6 + M72 fusion




FIG. 2

(57) Abstract: The disclosure relates to tuberculosis antigens and vectors for delivering the antigens. The disclosure also relates to immunogenic compositions comprising the same, and their uses.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))